CR11267A - Preparacion solida que contiene alogliptina y clorhidrato de metformina - Google Patents

Preparacion solida que contiene alogliptina y clorhidrato de metformina

Info

Publication number
CR11267A
CR11267A CR11267A CR11267A CR11267A CR 11267 A CR11267 A CR 11267A CR 11267 A CR11267 A CR 11267A CR 11267 A CR11267 A CR 11267A CR 11267 A CR11267 A CR 11267A
Authority
CR
Costa Rica
Prior art keywords
alogliptine
chlorhydrate
metformin
preparation containing
solid preparation
Prior art date
Application number
CR11267A
Other languages
English (en)
Inventor
Kazumichi Yamamoto
Hiroyoshi Koyama
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39930391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11267(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR11267A publication Critical patent/CR11267A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion proporciona una preparacion solida que contiene el compuesto (I) es como se define en la memoria descriptiva.
CR11267A 2007-07-19 2010-02-12 Preparacion solida que contiene alogliptina y clorhidrato de metformina CR11267A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007188574 2007-07-19

Publications (1)

Publication Number Publication Date
CR11267A true CR11267A (es) 2010-05-03

Family

ID=39930391

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11267A CR11267A (es) 2007-07-19 2010-02-12 Preparacion solida que contiene alogliptina y clorhidrato de metformina

Country Status (27)

Country Link
US (1) US8900638B2 (es)
EP (1) EP2185138B1 (es)
JP (2) JP5479318B2 (es)
KR (1) KR101536786B1 (es)
CN (1) CN101801351B (es)
AR (1) AR067557A1 (es)
AU (1) AU2008276842C9 (es)
BR (1) BRPI0814299B8 (es)
CA (1) CA2694620C (es)
CO (1) CO6160301A2 (es)
CR (1) CR11267A (es)
DO (1) DOP2010000028A (es)
EA (1) EA020870B1 (es)
EC (1) ECSP109979A (es)
ES (1) ES2603879T3 (es)
GE (1) GEP20125672B (es)
IL (1) IL203171A (es)
JO (1) JO3272B1 (es)
MA (1) MA31592B1 (es)
MY (1) MY159203A (es)
NZ (1) NZ583346A (es)
PE (2) PE20090882A1 (es)
TN (1) TN2010000019A1 (es)
TW (1) TWI421102B (es)
UA (1) UA98799C2 (es)
WO (1) WO2009011451A1 (es)
ZA (1) ZA201000831B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
AR067557A1 (es) * 2007-07-19 2009-10-14 Takeda Pharmaceutical Preparacion solida y metodo de preparacion
KR101612137B1 (ko) 2008-02-13 2016-04-12 다이닛본 스미토모 세이야꾸 가부시끼가이샤 구강 내 붕괴정
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CN103816158A (zh) 2008-08-15 2014-05-28 勃林格殷格翰国际有限公司 用于治疗fab-相关疾病的嘌呤衍生物
TW201014850A (en) 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
AU2010212823B2 (en) 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
CA2755561A1 (en) 2009-03-26 2010-09-30 Mapi Pharma Limited Process for the preparation of alogliptin
EP2429500B1 (en) * 2009-05-13 2015-01-14 Wyeth LLC Method to stabilize a dietary supplement comprising glucosamine
CN102740839B (zh) 2009-11-13 2015-05-06 阿斯利康(瑞典)有限公司 立即释放片剂
CN105193761B (zh) 2009-11-13 2019-12-06 阿斯利康(瑞典)有限公司 双层片剂
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2011141903A1 (en) * 2010-05-12 2011-11-17 Mapi Pharma Holdings (Cyprus) Limited Polymorphs of alogliptin benzoate
KR20200028498A (ko) 2010-06-24 2020-03-16 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
JP2012051832A (ja) * 2010-08-31 2012-03-15 Fancl Corp 顆粒組成物及びそれを含有する食品又は医薬品
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2013077825A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Preparation process for a formulation comprising metformin
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CA2922849A1 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
CN103877054B (zh) * 2012-12-21 2016-05-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
EP2769712A1 (en) * 2013-02-21 2014-08-27 Siegfried International AG Pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles
CN103353491B (zh) * 2013-06-29 2018-11-16 北京万全德众医药生物技术有限公司 一种用液相色谱法分离测定苯甲酸阿格列汀原料及其制剂的方法
WO2015012365A1 (ja) * 2013-07-25 2015-01-29 株式会社 三和化学研究所 医薬製剤
CN104749269B (zh) * 2013-12-31 2018-12-28 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定阿格列汀原料药及制剂中对映异构体杂质的方法
CN105527348B (zh) * 2014-09-28 2018-07-24 中美华世通生物医药科技（武汉）有限公司 分离分析苯甲酸阿格列汀制剂及其有关物质的方法
CN104569172A (zh) * 2014-11-05 2015-04-29 广东东阳光药业有限公司 一种用液相色谱检测苯甲酸阿格列汀片溶出度的方法
CN105675733B (zh) * 2014-11-17 2020-01-31 重庆医药工业研究院有限责任公司 一种用液相色谱法分离测定琥珀酸曲格列汀及其光学异构体的方法
KR102504959B1 (ko) * 2014-12-03 2023-03-02 카피탈리 시스템 에스.피.에이 음료 제조용 캡슐을 제조하기 위한 수용체 및 단일 형태의 수용체를 사용하여 서로 다른 분량의 분말 식품 재료를 구비하는 캡슐을 제조하기 위한 방법
CN107810005B (zh) * 2015-06-17 2021-04-20 赫克萨尔股份公司 阿格列汀制剂
WO2017029609A1 (en) * 2015-08-20 2017-02-23 Torrent Pharmaceuticals Limited Pharmaceutical composition of alogliptin and metformin
WO2017033115A1 (en) * 2015-08-21 2017-03-02 Alembic Pharmaceuticals Limited Stable pharmaceutical composition of alogliptin and metformin fixed dose combination
EP3368029A1 (en) 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
CN106008277A (zh) * 2016-06-12 2016-10-12 聊城大学 一种新型二甲双胍盐酸盐及其制备方法
CN106421794A (zh) * 2016-09-27 2017-02-22 黑龙江珍宝岛药业股份有限公司 一种用于治疗ⅱ型糖尿病的药物组合物及其制备方法
CN108318610A (zh) * 2017-12-29 2018-07-24 合肥拓锐生物科技有限公司 一种苯甲酸阿格列汀原料及其制剂中有关物质的分析方法
WO2020013777A2 (en) 2018-04-27 2020-01-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet formulations comprising metformin and sitagliptin
CN108743611A (zh) * 2018-06-20 2018-11-06 常州制药厂有限公司 一种复方利血平片的制备方法
WO2020098904A1 (en) 2018-11-12 2020-05-22 Pharmaceutical Oriented Services Ltd Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor
TR201907905A1 (tr) * 2019-05-24 2020-12-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Alogli̇pti̇n ve metformi̇n i̇çeren bi̇r kombi̇nasyon
CN111537622B (zh) * 2019-11-29 2021-11-26 杭州华东医药集团新药研究院有限公司 一种度格列汀及其盐的杂质的检测方法
WO2023059118A1 (ko) * 2021-10-08 2023-04-13 (주)셀트리온 안정성이 개선된 당뇨병 치료용 약학 조성물

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
JPS49110814A (es) * 1973-03-02 1974-10-22
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
EP1520582A3 (en) 1998-02-02 2009-07-01 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
ATE250418T1 (de) * 1998-07-15 2003-10-15 Merck Sante Sas Tabletten enthaltend eine kombination von glibenclamid und metformin
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
ITMI20002019A1 (it) 1999-09-17 2002-03-15 Novartis Ag Metodo per il trattemento dei disturbi metabolici, in particolare diabete oppure una malattia oppure una condizione associate con il diabete
EP1229918B1 (en) 1999-11-03 2008-03-26 Bristol-Myers Squibb Company Pharmaceutical composition comprising a combination of metformin and glibenclamide
CA2407149C (en) * 2000-04-28 2010-10-12 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
US6403121B1 (en) * 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
US6780432B1 (en) 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
CA2408913A1 (en) * 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
AU2002257582A1 (en) * 2001-02-14 2002-09-04 Glaxo Wellcome S.A. Pharmaceutical formulation
US6524618B1 (en) * 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
CA2682251A1 (en) 2001-07-17 2003-01-30 N-Gene Research Laboratories Inc. A synergistic pharmaceutical combination for the prevention or treatment of diabetes
BR0213079A (pt) * 2001-09-28 2004-11-09 Sun Pharmaceutical Ind Ltd Forma de dosagem para o tratamento da diabetes mellitus
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US20030224046A1 (en) * 2002-06-03 2003-12-04 Vinay Rao Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent
US20040125143A1 (en) 2002-07-22 2004-07-01 Kenneth Deaton Display system and method for displaying a multi-dimensional file visualizer and chooser
ATE461212T1 (de) 2002-09-18 2010-04-15 Prosidion Ltd Sekundäre bindungsstelle von dipeptidylpeptidase iv (dp iv)
NZ538936A (en) * 2002-09-26 2006-12-22 Eisai Co Ltd Combination drug comprising a combination of a dipeptidyl peptidase IV (DPPIV) inhibitor with biguanide
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
EP1506967B1 (en) 2003-08-13 2007-11-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
RU2367423C2 (ru) * 2003-12-19 2009-09-20 ОМЕГА БИО-ФАРМА (Ай.Пи. 3) ЛИМИТЕД Композиции и способы для лечения диабета
MXPA06010571A (es) 2004-03-15 2007-02-16 Takeda Pharmaceutical Inhibidores de dipeptidil peptidasa.
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
CA2622608C (en) 2005-09-14 2014-08-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
US8414921B2 (en) 2005-12-16 2013-04-09 Merck Sharp & Dohme Corp. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
NZ569661A (en) * 2005-12-28 2011-06-30 Takeda Pharmaceutical Therapeutic agent for diabetes
RU2333760C2 (ru) 2006-05-16 2008-09-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Твердая дозированная лекарственная форма для лечения сахарного диабета
TW200826936A (en) * 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JP5284967B2 (ja) * 2007-02-01 2013-09-11 武田薬品工業株式会社 打錠障害を生じない錠剤製剤
RS51592B (sr) 2007-02-01 2011-08-31 Takeda Pharmaceutical Company Limited Čvrsti preparat koji sadrži alogliptin i pioglitazon
AR067557A1 (es) * 2007-07-19 2009-10-14 Takeda Pharmaceutical Preparacion solida y metodo de preparacion
RU2380097C1 (ru) 2009-01-20 2010-01-27 Общество с ограниченной ответственностью "ИТЭРА" Твердая дозированная лекарственная форма для лечения сахарного диабета

Also Published As

Publication number Publication date
US20100136127A1 (en) 2010-06-03
BRPI0814299B1 (pt) 2018-12-18
EP2185138A1 (en) 2010-05-19
ECSP109979A (es) 2010-03-31
JO3272B1 (ar) 2018-09-16
JP5479318B2 (ja) 2014-04-23
UA98799C2 (ru) 2012-06-25
US8900638B2 (en) 2014-12-02
TN2010000019A1 (en) 2011-09-26
JP2014058547A (ja) 2014-04-03
PE20140923A1 (es) 2014-08-11
AU2008276842B2 (en) 2013-07-04
ZA201000831B (en) 2011-04-28
AR067557A1 (es) 2009-10-14
US20110014299A2 (en) 2011-01-20
AU2008276842C9 (en) 2014-08-21
CA2694620C (en) 2016-05-31
ES2603879T3 (es) 2017-03-01
CO6160301A2 (es) 2010-05-20
NZ583346A (en) 2012-02-24
DOP2010000028A (es) 2010-02-15
TWI421102B (zh) 2014-01-01
MA31592B1 (fr) 2010-08-02
TW200914066A (en) 2009-04-01
KR101536786B1 (ko) 2015-07-14
JP2010533643A (ja) 2010-10-28
EA020870B1 (ru) 2015-02-27
MY159203A (en) 2016-12-30
CA2694620A1 (en) 2009-01-22
GEP20125672B (en) 2012-10-25
CN101801351B (zh) 2012-12-12
AU2008276842C1 (en) 2013-11-28
PE20090882A1 (es) 2009-08-03
BRPI0814299B8 (pt) 2021-05-25
KR20100036367A (ko) 2010-04-07
CN101801351A (zh) 2010-08-11
WO2009011451A1 (en) 2009-01-22
BRPI0814299A2 (pt) 2015-02-03
EA201070164A1 (ru) 2010-08-30
IL203171A (en) 2016-11-30
EP2185138B1 (en) 2016-09-07
AU2008276842A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
CR11267A (es) Preparacion solida que contiene alogliptina y clorhidrato de metformina
UY31274A1 (es) Composiciones de recubrimiento electrodepositable que contiene una guanidina ciclica
HN2008000188A (es) 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
DE602008000754D1 (de) Tropanverbindungen
GT200800209A (es) Compuestos organicos
CR9280S (es) Botella
AR059194A1 (es) Formas de dosificacion resistentes a la manipulacion
CR10662A (es) Compuestos de metilpiridopirimidinona
CR10328A (es) Compuestos organicos
GT200700002S (es) Cubierta de recipiente
CR11123A (es) Compuestos triciclicos que contienen nitrogeno como agentes antibacteriales
SV2011003853A (es) Compuestos organicos
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
UY31563A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
UY31562A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
CR9344S (es) Regadera
UY31560A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
SV2011003800A (es) Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica
MX2009010103A (es) Composiciones estructuradas que comprenden una arcilla.
UY31688A1 (es) Plaguicidas
HN2006037713A (es) Compuestos utiles en terapia
PA8671301A1 (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricación y utilización
MX2009007764A (es) Formulacion de nevirapina de liberacion prolongada.
SV2009003253A (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
AR082215A1 (es) Composicion farmaceutica agradable al paladar